Xenon (XENE) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Xenon Pharmaceuticals has unveiled promising long-term data from its X-TOLE study, showing that its drug azetukalner significantly reduces seizure frequency in patients with focal onset seizures. Impressively, one-third of those treated for over three years achieved complete seizure freedom, highlighting the drug’s potential to improve epilepsy treatment.
For further insights into XENE stock, check out TipRanks’ Stock Analysis page.